Galectin-3 immunoassay
AssigneeBG Medicine, Inc.
InventorsPieter Muntendam, Shunguang Wang
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for specifically and quantitatively detecting galectin-3 in a sample. Embodiments of the invention include a detection assay in which a capture binding moiety and a labeled binding moiety specifically recognize non-overlapping epitopes on the N-terminus of galectin-3. Further embodiments are directed to a method for establishing ranges of galectin-3 concentrations indicative of the presence and severity of heart failure in a subject and a method for predicting the clinical outcome of a subject based upon galectin-3 concentration.
Claims29
A kit for detecting a concentration of galectin-3 in a sample, the kit comprising
- first and second binding moieties, one being labeled with a detectable label, wherein the first binding moiety comprises an M3/38 monoclonal antibody capable of binding to galectin-3, and wherein the second binding moiety comprises an 87B5 monoclonal antibody capable of binding to galectin 3.
(canceled)
(canceled)
A method for detecting the level of human galectin-3 in at least one sample from a subject, the method comprising:
- contacting the at least one sample with a first binding moiety capable of binding to galectin-3 comprising an M3/38 monoclonal antibody immobilized on a solid surface, wherein the first binding moiety captures the human galectin-3 in the at least one sample to form a first complex;
- contacting the first complex with a second binding moiety capable of binding to galectin-3 comprising an 87B5 monoclonal antibody and a detectable label, wherein the second binding moiety binds to the first complex to form a second complex comprising the detectable label;
- and
- detecting the detectable label of the second complex, thereby detecting the level of the human galectin-3 in the at least one sample.
A method for detecting a risk of development or progression of heart failure in a subject, the method comprising the steps of:
- obtaining from the subject at least one sample comprising whole blood, serum, or plasma;
- contacting the at least one sample with a first binding moiety capable of binding to galectin-3 comprising an M3/38 monoclonal antibody immobilized on a solid surface, wherein the first binding moiety captures the human galectin-3 in the at least one sample to form a first complex;
- contacting the first complex with a second binding moiety capable of binding to galectin-3 comprising a 87B5 monoclonal antibody and a detectable label, wherein the second binding moiety binds to the first complex to form a second complex comprising the detectable label;
- detecting the detectable label of the second complex, thereby detecting the level of the human galectin-3 in the at least one sample;
- and
- determining whether the level of the human galectin 3 exceeds a threshold of at least 15 ng/ml,
- thereby detecting the risk of development or progression of heart failure in the subject.
A method for detecting a level of a human galectin-3 in a sample from a subject, the method comprising:
- contacting the sample with a first binding moiety capable of binding to galectin-3 comprising a 87B5 monoclonal antibody immobilized on a solid surface, wherein the first binding moiety captures the human galectin-3 in the sample to form a first complex;
- contacting the first complex with a second binding moiety capable of binding to galectin-3 comprising an M3/38 monoclonal antibody and a detectable label, wherein the second binding moiety binds to the first complex to form a second complex comprising the detectable label;
- and
- detecting the detectable label of the second complex, thereby detecting the level of the human galectin-3 in the sample.
Dependencies are inferred from the claim text.